Llwytho...
A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability
Bevacizumab (BVZ) is a monoclonal antibody that binds to human vascular endothelial growth factor A (VEGF-A) and inhibits the interaction between VEGF-A and VEGF receptors, thus blocking the angiogenesis. Repeated intravitreal injections of BVZ for the treatment of ocular pathologies that present an...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Pharmaceutics |
|---|---|
| Prif Awduron: | , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8071554/ https://ncbi.nlm.nih.gov/pubmed/33921167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13040560 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|